Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
For the full year,net profit declined 2.71% to Rs 496.20 crore in the year ended March 2025 as against Rs 510.00 crore during the previous year ended March 2024. Sales rose 4.41% to Rs 3642.40 crore in the year ended March 2025 as against Rs 3488.60 crore during the previous year ended March 2024.
Syngene International Ltd, KIOCL Ltd, Glaxosmithkline Pharmaceuticals Ltd, Dalmia Bharat Ltd are among the other stocks to see a surge in volumes on BSE today, 24 April 2025.
Home First Finance Company India Ltd recorded volume of 4.22 lakh shares by 10:47 IST on BSE, a 25.89 times surge over two-week average daily volume of 16300 shares. The stock lost 0.68% to Rs.1,291.95. Volumes stood at 13752 shares in the last session.
Syngene International Ltd saw volume of 4.04 lakh shares by 10:47 IST on BSE, a 18.77 fold spurt over two-week average daily volume of 21535 shares. The stock dropped 10.01% to Rs.675.00. Volumes stood at 24206 shares in the last session.
KIOCL Ltd saw volume of 1.5 lakh shares by 10:47 IST on BSE, a 14.21 fold spurt over two-week average daily volume of 10565 shares. The stock increased 14.41% to Rs.290.20. Volumes stood at 7968 shares in the last session.
Glaxosmithkline Pharmaceuticals Ltd saw volume of 42095 shares by 10:47 IST on BSE, a 10 fold spurt over two-week average daily volume of 4210 shares. The stock increased 6.28% to Rs.3,029.95. Volumes stood at 2554 shares in the last session.
Dalmia Bharat Ltd registered volume of 45513 shares by 10:47 IST on BSE, a 8.78 fold spurt over two-week average daily volume of 5184 shares. The stock rose 3.71% to Rs.1,963.75. Volumes stood at 3151 shares in the last session.
For the full year, net profit declined 2.71% to Rs 496.20 crore while net sales rose 4.41% to Rs 3642.40 crore in the year ended March 2025 over the year ended March 2024. Reported EBITDA rose 1% year-on-year to Rs 1,114 crore in FY25. EBITDA margin (%) stood at 30% in FY25, lower than 30.9% in FY24.
In its outlook for FY26, the Syngene management anticipates the reported revenue growth will likely be in the mid-single digits. They also foresee the EBITDA margin moderating from current levels to the mid-twenties and a year-on-year decline in profit after tax.
Commenting on the results, Peter Bains, managing director and CEO, Syngene International, said, 'Looking at the year ahead, while the wider global market dynamics remain uncertain, we expect the business momentum to continue with pipeline build in both small and large molecules, supported by new pilot programs and conversion of existing pilots in discovery services. On an underlying basis for fiscal year 2026, we expect revenue growth in the early teens reflecting a broad-based growth across research, development and manufacturing services. Adjusted for inventory balancing in large molecule commercial manufacturing at client level, the reported revenue growth is likely to be at mid-single digit.'
Deepak Jain, chief financial officer, Syngene International, said, 'Looking ahead into the next financial year, we expect the momentum to continue, with reported revenue growth at the mid-single digit level. As we bring the new biologics manufacturing facilities into operations, the additional operating costs and depreciation will impact margins. With this, we expect EBITDA margin to moderate from current levels to the mid-twenties and year-on-year decline in profit after tax.'
The company's board recommended a final dividend of Re 1.25 per equity share for the financial year 2024-25.
Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.